Ketamine in Patients Undergoing TEVAR Procedures Receiving NCI

Part of paid clinical trials in Lexington, Kentucky.

Sponsor
Sam Tyagi
Study ID
NCT04600089
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Descending Aortic Dissection
  • Postoperative Pain
  • Thoracoabdominal Aortic Aneurysm

Eligibility Criteria

Sex
ALL
Age
18 Years - 90 Years
Healthy Volunteers
Not accepted

Interventions

  • Saline — DRUG
    Saline infusion
  • Ketamine — DRUG
    Continuous ketamine infusion at a dose of 0.2 mg/kg/hr, initiated at the induction of anesthesia and continued for 48 hours postoperatively.

Study Details

The objective of this study is to identify the opioid-sparing effects, and pain-reduction potential of low dose, sub-dissociative ketamine on patients undergoing thoracic endovascular aortic repair (TEVAR) procedures receiving naloxone continuous infusion (NCI).

Key Dates

Start date
Dec 8, 2020
Status verified
Oct 2025
Primary completion
Aug 31, 2027
Completion
Aug 31, 2027

Study Design

Enrollment
30 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Placebo Comparator: Standard of Care
    Participants in this group will receive standard of care as well as a saline infusion during the study period.
  • Experimental: Sub-Dissociative Ketamine
    Participants in this group will receive standard of care as well as a continuous ketamine infusion at the induction of anesthesia and for 48 hours postoperatively.

Primary Outcome Measure

Cumulative Opioid Dose [ Time Frame: 48 hours ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Kentucky Medical CenterLexingtonKentucky40536
Eric Johnson, PharmD
[email protected]
859-323-5722

Find similar trials in Lexington, KY

By research site
University of Kentucky Medical Center· Lexington, KY

Related Studies